Transport properties of pancreatic cancer describe gemcitabine delivery and response

Abstract

Background. The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) is partly ascribed to ineffective delivery of chemotherapy to cancer cells. We hypothesized that physical properties at vascular, extracellular, and cellular scales influence delivery of and response to gemcitabine-based therapy.Methods. We developed a method to measure mass transport properties during routine contrast-enhanced CT scans of individual human PDAC tumors. Additionally, we evaluated gemcitabine infusion during PDAC resection in 12 patients, measuring gemcitabine incorporation into tumor DNA and correlating its uptake with human equilibrative nucleoside transporter (hENT1) levels, stromal reaction, and CT-derived mass transport properties. We also studied associations between CT-derived transport properties and clinical outcomes in patients who received preoperative gemcitabine-based chemoradiotherapy for resectable PDAC.Results. Transport modeling of 176 CT scans illustrated striking differences in transport properties between normal pancreas and tumor, with a wide array of enhancement profiles. Reflecting the interpatient differences in contrast enhancement, resected tumors exhibited dramatic differences in gemcitabine DNA incorporation, despite similar intravascular pharmacokinetics. Gemcitabine incorporation into tumor DNA was inversely related to CT-derived transport parameters and PDAC stromal score, after accounting for hENT1 levels. Moreover, stromal score directly correlated with CT-derived parameters. Among 110 patients who received preoperative gemcitabine-based chemoradiotherapy, CT-derived parameters correlated with pathological response and survival.Conclusion. Gemcitabine incorporation into tumor DNA is highly variable and correlates with multiscale transport properties that can be derived from routine CT scans. Furthermore, pretherapy CT-derived properties correlate with clinically relevant endpoints.Trial registration. Clinicaltrials.gov NCT01276613.

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

“…FMX 0!72 tumor exposure parameters were estimated from FMX values derived from MRI using a simple linear piecewise function (33). We made the assumption that the difference in the contribution of local field inhomogeneities to R2 Ã on the different scan days (captured in the difference between R2 Ã 0,post and R2 Ã 0, pre ) is negligible relative to the change in R2 Ã produced by FMX (captured in the difference between R2 Ã post and R2 Ã pre ).…”

Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation

“…However, the treatments are still largely ineffective (4). The failure is attributable to many factors, including extrinsic (6) or intrinsic (7) resistance to the conventional therapeutic approaches of chemotherapy. The chemotherapeutic agent gemcitabine is usually the recommended first-line drug for patients with PDAC and is given alone or in combination with other agents (8).…”

Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture

“…Most tumors, however, will develop rapid resistance to these regimens and will continue to progress by unknown mechanisms. 2,3 As a result, both the median survival and annual death rate for patients with PC have remained unchanged over the past 20 years. 4 To this end, an analysis of phase 1 cancer trials, which used agents with demonstrated efficacy in models derived from established commercially available cancer cell lines, revealed an overall objective response rate in only 3.8% of patients.…”